Rayno Biopharma Portfolio: Update 4/11,6/11, and 11/11,21/11

11/18

Added Dendreon (DNDN) at $8.00 level.IBB is preferred biotech ETF.

11/15/11

Comments:

Under review: ImmunoGen (IMGN)

Dropped FBT an ETF in favor of  IBB or possibly XBI. For bullish equity allocation in Tech and Biotech use QQQ.

6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD.

Mid-cap biopharms are up 1.6% as of mid-day.

6/6/11 ASCO “sell on the news effect” continues.No new buys. Cash at 10-15%.

4/28/11: Take some profits. Biotech sector is very frothy and meteoric moves suggests caution. Raise a little cash from EXEL,CEPH, REGN and ETF’s.

Comments:

• Albany Molecular (AMRI) is  a turn-around play for 2011. Deleted weak performance.
• Targacept (TRGT) stock has stalled over the past several months.
• The Cephalon CEPH) buyout offer from Valeant (VRX) is pending.
• Micromet (MITI) and Nektar (NKTR)have underperformed and are under review.